Skip to content
DraconiticResearch
Search Sources API
182,549 studies31 sourcesUpdated 56 min ago
Peer-reviewedCC BY-NC-NDTrials

Accelerated intermittent theta burst stimulation (iTBS) for the upper limb recovery after subacute stroke (ATLAS): study protocol for a multicenter randomized controlled trial.

  1. 1Department of Rehabilitation, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
  2. 2Department of Rehabilitation, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China. [email protected].

Abstract

Background

Stroke is the second leading cause of death globally, with residual upper limb dysfunction being a major contributor to its high disability rate. Currently, there remains a lack of effective rehabilitation approaches to substantially improve upper limb dysfunction. While transcranial magnetic stimulation (TMS) has shown potential in promoting functional reorganization in stroke patients, more effective treatment protocols are still under exploration. In recent years, numerous clinical evidence has indicated that intermittent theta burst stimulation (iTBS) may offer a more efficient pathway for the upper limb recovery after stroke. A few studies have employed accelerated iTBS protocols, preliminarily confirming its safety and efficacy, yet large-sample comparative studies against the standard protocol are lacking. This ATLAS trial aims to compare the effects of accelerated iTBS versus a standard TMS protocol on upper limb recovery and overall functional outcomes in patients with subacute stroke.Methods

This is a prospective, single-blind, multicenter, randomized controlled clinical trial. A total of 240 patients in the subacute phase of stroke will be recruited from 13 hospitals across 11 cities. Participants will be randomly allocated to either an iTBS group or a low-frequency repetitive TMS (LF-rTMS) group. Both groups will receive treatment 5 days per week for three consecutive weeks. In addition, all participants will receive standard conventional rehabilitation therapies, including physical agent modalities, therapeutic exercise, occupational therapy, and other commonly used clinical rehabilitation approaches. The primary outcome is the Fugl-Meyer Assessment for Upper Extremity (FMA-UE) evaluated after 3 weeks of treatment. Secondary outcomes include measures of upper limb function, activities of daily living, clinical disease severity, and neurophysiological indicators assessed by rTMS, evaluated at both post-intervention and after a 3-week follow-up period.Discussion

ATLAS trial is the first multicenter randomized controlled trial to apply an accelerated iTBS protocol to a large cohort of patients with subacute stroke and compare it directly with a standard stimulation protocol. The findings are expected to address the current gap in high-quality evidence regarding the efficacy of accelerated iTBS on upper limb recovery after stroke, thereby promoting the broader clinical adoption of more efficient iTBS-based therapeutic strategies.Trial registration

Chinese Clinical Trial Registry (ChiCTR2500110766). Registered on Oct 20, 2025.

Related

  1. Advantage of cerebellar intermittent theta-burst stimulation in Alzheimer's disease (ACT-AD): study protocol for a multicenter, randomized, double-blind, sham-controlled trial
    Xin Zhang, Wen Li, Zhongqing Sun +12
    TrialsPeer-reviewedCC BY 4.0Full textNeurologyCrossref
  2. Accelerating tracheostomy decannulation with intermittent oro-esophageal feeding in neurogenic dysphagia: a multicenter randomized controlled trial.
    Qing Li, Danhong Hu, Bo Yang +7
    Critical care (London, England)Peer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  3. Copenhagen Magnetic Personalized Accelerated Brain Circuit Therapy (CoMPACT) trial: study protocol for a randomized, double-blinded, sham-controlled, three-armed, parallel-group trial of transcranial magnetic stimulation for treatment-resistant depression
    Armita Faghani Jadidi, Iman Ibrahim, Lasse Christiansen +10
    Frontiers in psychiatryPeer-reviewedCC BYFull textNeurologyEurope PMCCrossref
  4. Automated intermittent olfactory stimulation to reduce apnea in preterm infants: results of the PREMODEUR randomized clinical trial
    Hélène Gauthier-Moulinier, Huu Kim An Nguyen, Claire Fischer +8
    European Journal of PediatricsPeer-reviewedPublisher termsFull textPhysiologyHAL
  5. Effectiveness and Patient Compliance of a Needle-Free Injection System in Controlled Ovarian Stimulation in IVF Cycles: A Real-World, Investigator-Initiated, Retrospective, Multicenter, Observational Study
    Manish Banker, Manika Khanna, Baiju P Ahammed +2
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
BibTeX
@article{yang2026accelerated,
  title = {{Accelerated intermittent theta burst stimulation (iTBS) for the upper limb recovery after subacute stroke (ATLAS): study protocol for a multicenter randomized controlled trial.}},
  author = {Hong Yang and Tian Shu and Chunyu Duan and Lin Chen and Xin Zhang and Xinyue Xu and Yiyu Chen and Han Chen and Jingming Hou},
  journal = {Trials},
  year = {2026},
  month = jul,
  doi = {10.1186/s13063-026-09857-3},
  url = {https://europepmc.org/article/MED/42907915},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Accelerated intermittent theta burst stimulation (iTBS) for the upper limb recovery after subacute stroke (ATLAS): study protocol for a multicenter randomized controlled trial.
AU  - Hong Yang
AU  - Tian Shu
AU  - Chunyu Duan
AU  - Lin Chen
AU  - Xin Zhang
AU  - Xinyue Xu
AU  - Yiyu Chen
AU  - Han Chen
AU  - Jingming Hou
PY  - 2026
DA  - 2026/07/01
JO  - Trials
DO  - 10.1186/s13063-026-09857-3
UR  - https://europepmc.org/article/MED/42907915
AB  - Background  Stroke is the second leading cause of death globally, with residual upper limb dysfunction being a major contributor to its high disability rate. Currently, there remains a lack of effective rehabilitation approaches to substantially improve upper limb dysfunction. While transcranial magnetic stimulation (TMS) has shown potential in promoting functional reorganization in stroke patients, more effective treatment protocols are still under exploration. In recent years, numerous clinical evidence has indicated that intermittent theta burst stimulation (iTBS) may offer a more efficient pathway for the upper limb recovery after stroke. A few studies have employed accelerated iTBS protocols, preliminarily confirming its safety and efficacy, yet large-sample comparative studies against the standard protocol are lacking. This ATLAS trial aims to compare the effects of accelerated iTBS versus a standard TMS protocol on upper limb recovery and overall functional outcomes in patients with subacute stroke.Methods  This is a prospective, single-blind, multicenter, randomized controlled clinical trial. A total of 240 patients in the subacute phase of stroke will be recruited from 13 hospitals across 11 cities. Participants will be randomly allocated to either an iTBS group or a low-frequency repetitive TMS (LF-rTMS) group. Both groups will receive treatment 5 days per week for three consecutive weeks. In addition, all participants will receive standard conventional rehabilitation therapies, including physical agent modalities, therapeutic exercise, occupational therapy, and other commonly used clinical rehabilitation approaches. The primary outcome is the Fugl-Meyer Assessment for Upper Extremity (FMA-UE) evaluated after 3 weeks of treatment. Secondary outcomes include measures of upper limb function, activities of daily living, clinical disease severity, and neurophysiological indicators assessed by rTMS, evaluated at both post-intervention and after a 3-week follow-up period.Discussion  ATLAS trial is the first multicenter randomized controlled trial to apply an accelerated iTBS protocol to a large cohort of patients with subacute stroke and compare it directly with a standard stimulation protocol. The findings are expected to address the current gap in high-quality evidence regarding the efficacy of accelerated iTBS on upper limb recovery after stroke, thereby promoting the broader clinical adoption of more efficient iTBS-based therapeutic strategies.Trial registration  Chinese Clinical Trial Registry (ChiCTR2500110766). Registered on Oct 20, 2025.
SN  - 1745-6215
ER  -